Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion (DRAIN)
Primary Purpose
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Status
Completed
Phase
Phase 3
Locations
Italy
Study Type
Interventional
Intervention
Loop Diuretics
Sponsored by
About this trial
This is an interventional treatment trial for Heart Failure NYHA Class III
Eligibility Criteria
Inclusion Criteria:
- Advanced heart failure
- WET ≥ 12
- Systolic blood pressure ≤ 110 mmHg
- Serum sodium ≤ 135 mEq/L
- Left systolic ventricular insufficiency (FE < 35%) note for at least 6 months
- Class NYHA III-IV despite medical treatment maximal
Exclusion Criteria:
- Acute coronary syndrome
- Shock cardiogenic
- Chronic renal failure stage V
Sites / Locations
- Simone Frea
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Continuous infusion of loop diuretics
Intermittent infusion of loop diuretics
Arm Description
Furosemide continuous infusion: 125 or 250 mg die
Furosemide bolus intermittent: 125 or 250 mg die
Outcomes
Primary Outcome Measures
Freedom from congestion
Secondary Outcome Measures
Worsening of renal function
Increase in creatinine value > 0.3 mg/dl or increase > 1.5 times
Worsening or persistent HF at 72 h
Need to increase the dose of inotropes or diuretics
Change in body weight
Laboratory data variations in NTproBNP
Treatment failure
Composed by the following events: persistence of congestion, need to increase diuretic treatment, need of renal replacement treatment
Weight differences based on diuretic dose unity
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03592836
Brief Title
Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion
Acronym
DRAIN
Official Title
Diuretic Treatment in High Risk Decompensated Advanced Heart Failure. Bolus Intermittent Versus Continuous Infusion of Furosemide: a Randomized Controlled Trial.
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
May 1, 2013 (Actual)
Primary Completion Date
December 22, 2017 (Actual)
Study Completion Date
December 22, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Turin, Italy
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Loop diuretics are the main therapy for decongestion of patients with advanced acute heart failure. However, these patients often develop diuretic-resistance or even diuretic-refractoriness. In order to overcome such resistance to diuretic, the clinician can increase the dose of furosemide, or change the way of administration (continuous infusion versus boluses) or associate a different class of diuretics (thiazide diuretics, K+-sparing diuretics) up to the addition of low doses of inotropic agents to improve renal perfusion. At the present time there is no evidence in literature in advanced acute heart failure patients about the superiority of the treatment with furosemide in continuous infusion or in intermittent boluses. The aim of the study was to evaluate the efficacy of furosemide in boluses versus continuous infusion in advanced acute heart failure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
80 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Continuous infusion of loop diuretics
Arm Type
Active Comparator
Arm Description
Furosemide continuous infusion: 125 or 250 mg die
Arm Title
Intermittent infusion of loop diuretics
Arm Type
Active Comparator
Arm Description
Furosemide bolus intermittent: 125 or 250 mg die
Intervention Type
Drug
Intervention Name(s)
Loop Diuretics
Other Intervention Name(s)
furosemide
Intervention Description
intravenous administration of diuretics
Primary Outcome Measure Information:
Title
Freedom from congestion
Time Frame
72 hours after randomization
Secondary Outcome Measure Information:
Title
Worsening of renal function
Description
Increase in creatinine value > 0.3 mg/dl or increase > 1.5 times
Time Frame
72 hours after randomization
Title
Worsening or persistent HF at 72 h
Description
Need to increase the dose of inotropes or diuretics
Time Frame
72 hours after randomization
Title
Change in body weight
Time Frame
72 hours after randomization
Title
Laboratory data variations in NTproBNP
Time Frame
72 hours after randomization
Title
Treatment failure
Description
Composed by the following events: persistence of congestion, need to increase diuretic treatment, need of renal replacement treatment
Time Frame
72 hours after randomization
Title
Weight differences based on diuretic dose unity
Time Frame
72 hours after randomization
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Advanced heart failure
WET ≥ 12
Systolic blood pressure ≤ 110 mmHg
Serum sodium ≤ 135 mEq/L
Left systolic ventricular insufficiency (FE < 35%) note for at least 6 months
Class NYHA III-IV despite medical treatment maximal
Exclusion Criteria:
Acute coronary syndrome
Shock cardiogenic
Chronic renal failure stage V
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simone Frea, MD
Organizational Affiliation
A.O.U. Città della Salute e della Scienza di Torino
Official's Role
Principal Investigator
Facility Information:
Facility Name
Simone Frea
City
Torino
State/Province
To
ZIP/Postal Code
10126
Country
Italy
12. IPD Sharing Statement
Citations:
PubMed Identifier
31256261
Citation
Frea S, Pidello S, Volpe A, Canavosio FG, Galluzzo A, Bovolo V, Camarda A, Golzio PG, D'Ascenzo F, Bergerone S, Rinaldi M, Gaita F. Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure-bolus intermittent vs. continuous infusion of furosemide: a randomized controlled trial. Clin Res Cardiol. 2020 Apr;109(4):417-425. doi: 10.1007/s00392-019-01521-y. Epub 2019 Jun 29.
Results Reference
derived
Learn more about this trial
Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion
We'll reach out to this number within 24 hrs